AGIO

Agios Pharmaceuticals, Inc. Health Care Pharmaceutical Preparations Russell 3000

$30.55Close $1.8BMarket cap $22.34 – $45.4952-week range Nov 5, 2026Next report · before the open

Highlights

Cautions

Not in an uptrend 4 of 8 trend conditions
Lagging the market RS 40 · weaker than 60% of stocks over 12 months
Far from its high 33% below its 52-week high
Results soon Nov 5, 2026, in 4 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Jul 30, 2026

Off 12-month high 33%

1wk 17.4% price change

1mo 8.1% price change

12-month return 29% market up 11% · its own down 38%

F-score 2 / 9 Weak

Altman Z 9.32 Low risk

P/E — price / earnings

PEG — P/E / EPS growth

P/B 1.5× price / book

Earnings yield 27.8% EBIT / enterprise value

Cheaper than 29% of the market · expensive

Revenue growth 48% year on year

EPS growth — latest quarter

Sales growth 259% latest quarter · +122 pts

ROE 30% return on equity

Free cash margin 698% -$377.3M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Piotroski tests

not yet profitable on its assets
operating cash flow is negative
profitability slipped from last year
short-term liquidity weakened
issued more shares
gross margin narrowed
assets working less efficiently
profits backed by cash
reduced long-term debt

Trade setup

ATR% 6.4% $1.94 a day · 2×ATR $26.66

RS 40 / 99 vs the universe

Trend 4 / 8 trend template

Relative volume 3.0× vs 50-day average

Up/down volume 1.02 50 sessions

Implied move — no option chain · report Nov 5, 2026

Trend template · 4 of 8

Price above the 150 and 200-day averages: fails
150-day average above the 200-day: passes
200-day average rising for a month: passes
50-day average above the 150 and 200-day: passes
Price above the 50-day average: fails
At least 30% above the 52-week low: passes
Within 25% of the 52-week high: fails
RS rank 70 or higher: fails

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Shareholders diluted The share count rose 2.3% over the year, from 57m to 58m shares. Each existing share owns a smaller fraction of the company than it did a year ago.

Last reported Jul 30, 2026

Last shock Oct 30, 2026-18% in one session2.9× volumeno filing matched0% since

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $54.0M +48% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$413.0M down to a loss

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$377.3M

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Gross 88%
Net -764%
Free cash -698%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 58.45m -15.7% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$0	$0	$14.2M	$26.8M	$36.5M	$54.0M
Gross margin	—	—	88%	89%	89%	88%
Operating income	-$335.9M	-$378.4M	-$389.0M	-$391.5M	-$425.7M	-$472.1M
Net income	-$327.4M	$1.6B	-$232.0M	-$352.0M	$674.0M	-$413.0M
Net margin	—	—	-1629%	-1312%	1847%	-764%
Earnings per share	-$4.74	$26.55	-$4.23	-$6.33	$11.64	-$7.12
Free cash flow	-$304.9M	-$413.1M	-$314.4M	-$297.1M	-$391.5M	-$377.3M
Free cash margin	—	—	-2208%	-1107%	-1073%	-698%
Cash	$127.4M	$203.1M	$139.3M	$88.2M	$76.2M	$89.1M
Shareholders' equity	$399.5M	$1.3B	$1.1B	$811.0M	$1.5B	$1.2B
Shares outstanding	69.29m	54.33m	55.04m	55.95m	57.16m	58.45m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Jul 30, 2026	Quarterly ↗	Jun 30, 2026	30d
Apr 29, 2026	Quarterly ↗	Mar 31, 2026	29d
Feb 12, 2026	Annual ↗	Dec 31, 2025	43d
Oct 30, 2025	Quarterly ↗	Sep 30, 2025	30d
Jul 31, 2025	Quarterly ↗	Jun 30, 2025	31d
May 1, 2025	Quarterly ↗	Mar 31, 2025	31d
Feb 13, 2025	Annual ↗	Dec 31, 2024	44d
Oct 31, 2024	Quarterly ↗	Sep 30, 2024	31d
Aug 1, 2024	Quarterly ↗	Jun 30, 2024	32d
May 2, 2024	Quarterly ↗	Mar 31, 2024	32d
Feb 15, 2024	Annual ↗	Dec 31, 2023	46d
Nov 2, 2023	Quarterly ↗	Sep 30, 2023	33d

Current reports

Filed	Disclosed
Jul 30, 2026	Results ↗
Jun 18, 2026	Director or officer change · Shareholder vote ↗
Apr 29, 2026	Results ↗
Feb 12, 2026	Results ↗
Jan 12, 2026	Regulation FD ↗
Oct 30, 2025	Results ↗
Aug 4, 2025	Regulation FD ↗
Jul 31, 2025	Results ↗
Jul 8, 2025	Director or officer change ↗
Jun 18, 2025	Director or officer change · Shareholder vote ↗
May 1, 2025	Results ↗
Feb 13, 2025	Results ↗